Screen Shot 2018-10-20 at 9.52.53 AM.png



David Sable, MD directs healthcare and life science investing for the Special Situations Funds and is portfolio manager of the Special Situations Life Sciences Fund. 

After graduating from the Wharton School and the University of Pennsylvania School of Medicine, David trained in obstetrics and gynecology at New York Hospital - Cornell Medical Center, and in reproductive endocrinology at the Brigham and Women's Hospital. He co-founded and served as director of the Institute for Reproductive Medicine and Science at Saint Barnabas Medical Center in New Jersey, was founder and CEO of Assisted Reproductive Medical Technologies, which was acquired by Saint Barnabas in 1999, and co-founder of Reprogenetics, acquired by Cooper Surgical in 2015. After leaving clinical medicine, Dr. Sable managed a proprietary healthcare portfolio at Deutsche Bank before joining the Special Situations Funds. 

David is an adjunct in the department of biology at Columbia University, and teaches “Entrepreneurship in Biotechnology” at Columbia’s Graduate School of Arts and Sciences. He has lectured on healthcare investing, policy, and biotechnology business development at the Wharton School, NYU, Rockefeller University and Rutgers; has delivered keynote addresses to the American Fertility Society, the Texas Fertility Society and the Mexican Fertility Society; and appeared on the CBS Morning News, ABC World News Tonight, NY1 News and PBS’ Nova to discuss innovation in reproductive medicine. He has served as a board member for Genenews Inc, Hamilton Thorne Ltd, and for the nonprofit advocacy organization RESOLVE, and on the medical and scientific advisory boards of Ovascience and Progyny.  In addition to his academic publications, he is a regular contributor to Forbes, covering the reproductive medicine industry.